Galenika a.d.

Galenika a.d. (Serbian Cyrillic: Галеника а.д.) is a Serbian pharmaceutical company with headquarters in Zemun, Belgrade.

Galenika a.d.
Native name
Галеника а.д.
Joint-stock company
Traded asBELEX: FITO
IndustryPharmaceuticals
Founded30 April 1991 (1991-04-30) (Current form)
First founded in 1945
Headquarters
Batajnički drum bb, Zemun
,
Serbia
Key people
Reinhard Andreas Dr. Nordmann (General director)
ProductsGeneric drugs, over-the-counter drugs, medical devices
Revenue €34.54 million (2018)[1]
(€10.73 million) (2018)[1]
Total assets €102.45 million (2018)[2]
Total equity €56.13 million (2018)[2]
OwnerAelius (93.73%)
Others
Number of employees
965 (2018)
SubsidiariesGaling d.o.o.
Galenika Banja Luka d.o.o.
Galenika Crna Gora d.o.o.
Galenika Klirit d.o.o.
Websitewww.galenika.rs

History

Founded in 1945, Galenika was a major pharmaceutical drug-maker in the Balkans with exports to Europe, Africa and Asia. During its golden times, it was the greatest Yugoslav pharmaceutical company which controlled over 65% of SFR Yugoslavia market share.[3]

In 1991, the company was bought by American ICN Pharmaceuticals, led by Serbian American businessman Milan Panić.[3] Even during the 1990s Yugoslav Wars and massive debts of FR Yugoslavia toward the company, it kept operating positive. In 1999, by political decision of Slobodan Milošević's regime, the FR Yugoslavia took over the majority stake of the company.[3] Following the overthrow of Slobodan Milošević in October 2000, the company returned on track and each year had tens of million euros of positive net income. As of 2006, Galenika remained a leader in research and development as the only pharmaceutical company in Serbia with an institute registered with the Ministry of Science and Environmental Protection.[4]

However, from 2008 to 2010, Galenika rapidly accumulated debt to the point where it owed 130 million euros.[3] Once controlling a majority market share in Serbia and former Yugoslavia, during the 2010s it became indebted company. By the 2010s, most of the Serbian formerly domestically controlled pharmaceutical market, has shifted in foreign hands.[5]

Since 2013, the Government of Serbia has begun seeking a partner for Galenika through the privatization process.[6] However, over the years several privatization auction processes have failed.

In August 2017, the Government of Serbia converted company's debts to state into shares in ownership structure, worth 14.696 billion dinars (122.81 million euros).[7] As of 2017, Galenika controlled around 10% of market share in Serbia.[3] In November 2017, Luxembourg's investment fund Aelius (related to the Brazilian largest pharmaceutical company EMS) purchased 93.73% of the company's shares from the Government of Serbia for a total of 16 million euros.[8]

Logos

From 1945, Galenika has changed four different logos. The first logo of company was used from 1945 to 1992, the second logo from 1992 to 1998 (which has been marked as ICN Galenika), the third logo was used from 1998 to 2002, and the fourth and incumbent logo has been in use since 2002.

Market and financial data

According to 2016 annual financial report submitted to Serbian Business Registers Agency (APR), the company has 1,595 employees and it posted an annual loss of 10.45 million euros. As of 30 January 2018, Galenika has a market capitalization of €63.17 million.[9]

Fraud

In October 2018, several high-ranking former officials of the company were sentenced before Belgrade's Special Court for the "fraud by abuse of position", in which they damaged the company for multimillion-euro bills.[10]

References
  1. "КОНСОЛИДОВАНИ БИЛАНС УСПЕХА (2018) - Галеника". apr.gov.rs (in Serbian). Retrieved 10 August 2019.
  2. "КОНСОЛИДОВАНИ БИЛАНС СТАЊА (2018) - Галеника". apr.gov.rs (in Serbian). Retrieved 10 August 2019.
  3. Stojaković, Dušan (16 October 2017). "Kako je uništavana "Galenika"". b92.net (in Serbian). Večernje Novosti. Retrieved 2 December 2018.
  4. Doing Business with Serbia By Marat Terterov, Consultant Editor, Marat Terterov, Inc NetLibrary; Published by GMB Publishing Ltd, 2006; ISBN 1-905050-68-2, ISBN 978-1-905050-68-0.
  5. Telesković, Anica (23 September 2017). "Stranci drže više od dve trećine tržišta lekova". politika.rs (in Serbian). Retrieved 12 November 2017.
  6. "Serbia to Start Sale of Galenika Drugmaker in Early 2013". Bloomberg. 13 December 2012. Retrieved 9 April 2013.
  7. "Država povećala vlasnički udeo u Galenici". blic.rs (in Serbian). Tanjug. 14 August 2017. Retrieved 9 October 2018.
  8. "Potpisano: Galenika prodata Eliusu". b92.net (in Serbian). 2 November 2017. Retrieved 12 November 2017.
  9. "FITO - Galenika Fitofarmacija a.d. , Zemun - 30.01.2018". belex.rs. Retrieved 30 January 2018.
  10. "Šest godina zatvora bivšem direktoru "Galenike"". b92.net (in Serbian). Beta. 19 October 2018. Retrieved 19 October 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.